The estimated Net Worth of Hideki Nagao is at least $195 mil dollars as of 21 November 2022. Mr. Nagao owns over 5,583 units of Medicinova Inc stock worth over $13,238 and over the last 18 years he sold MNOV stock worth over $51,241. In addition, he makes $130,800 as Independent Director at Medicinova Inc.
Sign up
Mr. Nagao MNOV stock SEC Form 4 insiders trading
Hideki has made over 7 trades of the Medicinova Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 6,754 units of MNOV stock worth $15,197 on 28 November 2022.
The largest trade he's ever made was exercising 15,000 units of Medicinova Inc stock on 6 August 2020 worth over $38,700. On average, Hideki trades about 1,778 units every 72 days since 2007. As of 21 November 2022 he still owns at least 6,754 units of Medicinova Inc stock.
You can see the complete history of Mr. Nagao stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Hideki Nagao biography
Hideki Nagao serves as Independent Director of the Company. He complements the MediciNova Board with 40 years of experience in finance and corporate law with financial institutions in Japan. Mr. Nagao started his career at Development Bank of Japan and, in 2006, he accepted the position of General Manager, Department of Venture Business Finance. In 2008, he moved to SG Holdings Co. Ltd. In 2009, Mr. Nagao served as President Sagawa Financials, Inc., as Director of Sagawa Global Logistics in 2012 and as President of SG Assetmax Co. Ltd in 2013. Currently, Mr. Nagao is an Auditor at Japan Economic Research Institute Inc.. Mr. Nagao holds a degree from the Faculty of Law of Tokyo University. He previously served as a Board Member for MediciNova from 2004 – 2010.
What is the salary of Hideki Nagao?
As the Independent Director of Medicinova Inc, the total compensation of Hideki Nagao at Medicinova Inc is $130,800. There are 5 executives at Medicinova Inc getting paid more, with Yuichi Iwaki having the highest compensation of $3,761,890.
How old is Hideki Nagao?
Hideki Nagao is 63, he's been the Independent Director of Medicinova Inc since 2017. There are 2 older and 8 younger executives at Medicinova Inc. The oldest executive at Medicinova Inc is Dr. Yuichi Iwaki M.D., Ph.D., 71, who is the Co-Founder, Pres, CEO & Exec. Director.
What's Hideki Nagao's mailing address?
Hideki's mailing address filed with the SEC is C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA, CA, 92037.
Insiders trading at Medicinova Inc
Over the last 18 years, insiders at Medicinova Inc have traded over $200,908 worth of Medicinova Inc stock and bought 459,744 units worth $1,581,779 . The most active insiders traders include Jeff Himawan, Masatsune Okajima y Yuichi Iwaki. On average, Medicinova Inc executives and independent directors trade stock every 95 days with the average trade being worth of $74,094. The most recent stock trade was executed by Hideki Nagao on 28 November 2022, trading 6,754 units of MNOV stock currently worth $15,197.
What does Medicinova Inc's logo look like?
Complete history of Mr. Nagao stock trades at Medicinova Inc
Medicinova Inc executives and stock owners
Medicinova Inc executives and other stock owners filed with the SEC include:
-
Yuichi Iwaki,
President, Chief Executive Officer, Director -
Kazuko Matsuda,
Chief Medical Officer, Director -
Geoffrey O'brien,
Vice President -
Dr. Yuichi Iwaki M.D., Ph.D.,
Co-Founder, Pres, CEO & Exec. Director -
Dr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D.,
Chief Medical Officer & Director -
Hideki Nagao,
Independent Director -
Carolyn Beaver,
Director -
Edward Stepanow,
Chief Financial Officer -
Jeffrey Himawan,
Independent Chairman of the Board -
John O'Neil CPA,
Controller -
Dr. David H. Crean Ph.D.,
Chief Bus. Officer -
Dr. Federico Gaeta Ph.D.,
Chief Scientific Officer -
Douglas G Paulin CPA, CPA,
Chief Financial Officer -
Yutaka Kobayashi,
Director -
Yoshio Ishizaka,
Director -
Masatsune Okajima,
VP and Head of Japanese Office -
Federico C.A. Gaeta,
Chief Scientific Officer -
Tatsuo Izumi,
Director -
Den Boom Esther Van,
Chief Financial Officer -
Jeff Himawan,
Director -
John K A Prendergast,
Director -
Hiroaki Shigeta,
Director -
Kirk William Johnson,
Chief Scientific Officer -
Arlene Morris,
Director -
Michael Denis Coffee,
Chief Business Officer -
David D O'toole,
Director -
Alan W Dunton,
Director -
Shintaro Asako,
VP and Chief Financial Officer -
Richard E Sr Gammans,
Chief Development Officer -
Daniel Vapnek,
Director -
Kenneth W Locke,
Chief Scientific Officer -
Michael E Kalafer,
Chief Medical Officer -
Nicole Lemerond,
Director